FDA

News

Amgen and UCB re-file Evenity for US approval

Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that the additional data they have provided will help overcome the FDA’s pre

News

FDA commissioner says more patients can expect ability to ar...

Scientific and medical advances are giving the US Food and Drug Administration (FDA) more opportunities to address diseases and illness.

News

Amgen faces first Neulasta biosimilar rival as FDA approves ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic.

Partner Content

Pre-Filled Syringes West Coast Conference

Partner Content

Last available seats at PFS West Coast Conference next week

SMi Group: To reserve the last available seats at the Pre-Filled Syringes West Coast Conference taking place on June 4-5 in San Diego CA, USA, contact Fateja Begum - fbegum@smi-online.co.uk / +44 (

News

FDA backs Novartis' Gilenya in paediatric MS

First disease modifying therapy approved in paediatric MS

Partner Content

Pre-Filled Syringes West Coast conference and exhibition

Partner Content

SMi's Pre-Filled Syringes West Coast conference and exhibiti...

In just 3 weeks, SMi Group will open its doors to host the next instalment in this year’s PFS conference series, 3rd annual Pre-Filled Syringes West Coast (June 4 – 5, San Diego).

Amgen and UCB re-file Evenity for US approval

FDA commissioner says more patients can expect ability to ar...

Amgen faces first Neulasta biosimilar rival as FDA approves ...

Last available seats at PFS West Coast Conference next week

FDA backs Novartis' Gilenya in paediatric MS

SMi's Pre-Filled Syringes West Coast conference and exhibiti...

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks